Monkeypox Treatment Market - Distribution by Type of Product (Therapeutics and Vaccines), Drug Developers, Drug Candidates, Type of Diagnostic Kit (PCR Kits, Antigen Detection Kits and Antibody Detection Kits), Type of End User (Hospitals and Clinics, Diagnostic Laboratories and Other End Users) and Key Geographical Regions ( North America (US, Canada), Europe (UK, Germany, Spain, France, Italy, Rest Of Europe) and Asia-Pacific (Japan, Australia)): Industry Trends and Global Forecasts, 2023-2035
The global monkeypox therapeutics and vaccines market is expected to reach USD 140 million in 2023 anticipated to grow at a stable forecast during the forecast period 2023-2035.
Monkeypox, an orthopox virus, presents symptoms similar to smallpox but is generally considered less severe. However, there has been a recent surge in reported cases in countries where it's not common. This escalation has made monkeypox a significant global health concern. In response, the World Health Organization (WHO) declared it a Public Health Emergency of International Concern (PHEIC) in July 2022. With over 71,000 reported cases globally, the situation is serious, prompting extensive efforts in research and development. Efforts focus on creating treatments and vaccines for both treating and preventing monkeypox. Currently, more than 25 therapeutics and vaccines are in various stages of development or commercialization specifically targeting this disease. The rising cases have also increased the demand for testing methods to quickly identify and diagnose the disease. This increased demand for testing is a result of the outbreak's expanding scale.
Report Coverage
Monkeypox, an orthopox virus, presents symptoms similar to smallpox but is generally considered less severe. However, there has been a recent surge in reported cases in countries where it's not common. This escalation has made monkeypox a significant global health concern. In response, the World Health Organization (WHO) declared it a Public Health Emergency of International Concern (PHEIC) in July 2022. With over 71,000 reported cases globally, the situation is serious, prompting extensive efforts in research and development. Efforts focus on creating treatments and vaccines for both treating and preventing monkeypox. Currently, more than 25 therapeutics and vaccines are in various stages of development or commercialization specifically targeting this disease. The rising cases have also increased the demand for testing methods to quickly identify and diagnose the disease. This increased demand for testing is a result of the outbreak's expanding scale.
Report Coverage
- The report examines the monkeypox treatment market, focusing on type of product, drug developers, drug candidates, type of diagnostic kit, end user and key geographical regions.
- Analyzing factors such as drivers, restraints, opportunities, and challenges, the report assesses their impact on market growth.
- It evaluates potential advantages and obstacles for stakeholders, providing insights into the competitive landscape for market leaders.
- Revenue forecasts are provided for market segments across three major regions.
- An executive summary consolidates research insights, offering a high-level overview of the present state and expected trajectory of the monkeypox market in the mid to long term.
- An introductory section covers the monkeypox virus, encompassing symptoms, historical outbreaks, transmission modes from animals to humans, and among humans. It also discusses diagnostic procedures, current treatments/vaccines, and future prospects.
- A comprehensive assessment of the current market landscape for monkeypox therapeutics/vaccines includes analysis of development stages, product types, molecular compositions, dosage forms, routes of administration, and detailed developer profiles.
- An extensive evaluation of the market landscape for monkeypox diagnostic kits covers parameters such as sample types, components, virus clades detected, detection methods, application areas, types, quantities, turnaround times, limit of detection, tests per kit, shelf life, and storage temperatures.
- A product competitiveness analysis of monkeypox detection kits considers parameters like developer experience, virus clade detection, components, sample usage, turnaround time, tests per kit, storage conditions, shelf life, detection methods, and kit types.
- Elaborate profiles of key stakeholders involved in monkeypox therapeutics/vaccines and diagnostic kit development are provided, including company overviews, product portfolios, recent developments, and future outlooks.
- A detailed analysis of partnerships formed between stakeholders from 2018 to 2022 covers agreements such as supply, product development, acquisitions, distribution, research and technology integration.
- An examination of grants received since 2003 by entities engaged in this field includes award details, funding amounts, institutes, grant types, purposes, program officers, recipient organizations, and departmental affiliations.
- A thorough analysis of over 200 peer-reviewed scientific articles in the last five years covers publication details, journals, keywords, publishers, affiliations, and geographical distributions.
- A qualitative analysis employing Porter's Five Forces framework examines threats of new entrants, bargaining power of stakeholders, threats of substitutes, and rivalry among competitors.
- Software
- Elabscience
- Goldsite Diagnostics
- Hangzhou Testsea Biotechnology
- Jiangsu Bioperfectus Technologies
- Lansion Biotechnology
- Bavarian Nordic
- Emergent BioSolutions
1. EXECUTIVE SUMMARY
2. INTRODUCTION
2.1. An Overview of Monkeypox
2.2. Signs and Symptoms
2.3. History of Disease Outbreaks
2.4. Disease Transmission
2.5. Disease Diagnosis
2.6. Prevention and Treatment
2.6.1 Prevention Measures
2.6.2 Available Therapeutics and Vaccines
2.7. Future Perspectives
3. MARKET LANDSCAPE: MONKEYPOX THERAPEUTICS AND VACCINES
3.1. Monkeypox Therapeutics and Vaccines: Overall Market Landscape
3.1.1 Analysis by Phase of Development
3.1.2 Analysis by Type of Product
3.1.3 Analysis by Phase of Development and Type of Product
3.1.4 Analysis by Type of Molecule
3.1.5 Analysis by Type of Dosage Form
3.1.6 Analysis by Route of Administration
3.2. Monkeypox Therapeutics and Vaccines: Developer Landscape
3.2.1 Analysis by Year of Establishment
3.2.2 Analysis by Type of Player
3.2.3 Analysis by Geography (Region-wise)
3.2.4 Analysis by Company Size and Geography (Region-wise)
3.2.5 Leading Developers: Analysis by Number of Therapeutics / Vaccines
4. MARKET LANDSCAPE: MONKEYPOX DIAGNOSTIC KITS
4.1. Monkeypox Diagnostic Kits: Overall Market Landscape
4.1.1. Analysis by Type of Sample
4.1.2. Analysis by Type of Kit Component
4.1.3. Analysis by Clade of Virus Detected
4.1.4. Analysis by Detection Method
4.1.5. Analysis by Application Area
4.1.6. Analysis by Type of Kit
4.1.7. Analysis by Quantity of Sample
4.1.8. Analysis by Turnaround Time
4.1.9 Analysis by Limit of Detection
4.1.10. Analysis by Number of Tests per Kit
4.1.11 Analysis by Shelf Life
4.1.12 Analysis by Storage Temperature
4.2 Monkeypox Diagnostic Kits: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Developer
4.2.6. Key Developers: Analysis by Number of Diagnostic Kits Developed
5. MONKEYPOX DIAGNOSTIC KITS: PRODUCT COMPETITIVENESS ANALYSIS
5.1. Methodology
5.2. Product Competitiveness Analysis: Monkeypox Diagnostic Kits
6. COMPANY PROFILES: MONKEYPOX THERAPEUTICS AND VACCINES DEVELOPERS
6.1. Bavarian Nordic
6.1.1. Company Overview
6.1.2. Monkeypox Therapeutics / Vaccines Portfolio
6.1.3. Recent Developments and Future Outlook
6.2. Emergent BioSolutions
6.2.1. Company Overview
6.2.2. Monkeypox Therapeutics / Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook
7. COMPANY PROFILES: MONKEYPOX DIAGNOSTIC KITS DEVELOPERS
7.1. ACON Laboratories
7.1.1. Company Overview
7.1.2. Monkeypox Diagnostic Kits Portfolio
7.2. altona Diagnostics
7.2.1. Company Overview
7.2.2. Monkeypox Diagnostic Kits Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. DNA Software
7.3.1. Company Overview
7.3.2. Monkeypox Diagnostic Kits Portfolio
7.4. Elabscience
7.4.1. Company Overview
7.4.2. Monkeypox Diagnostic Kits Portfolio
7.5. Goldsite Diagnostics
7.5.1. Company Overview
7.5.2. Monkeypox Diagnostic Kits Portfolio
7.6. Hangzhou Testsea Biotechnology
7.6.1. Company Overview
7.6.2. Monkeypox Diagnostic Kits Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Jiangsu Bioperfectus Technologies
7.7.1. Company Overview
7.7.2. Monkeypox Diagnostic Kits Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. Lansion Biotechnology
7.8.1. Company Overview
7.8.2. Monkeypox Diagnostic Kits Portfolio
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Partnerships and Collaborations
8.1.1. Analysis by Year of Partnership
8.1.2. Analysis by Type of Partnership
8.1.3. Analysis by Year and Type of Partnership
8.1.4. Analysis by Focus Area
8.1.5. Analysis by Type of Partner
8.1.6. Most Active Players: Analysis by Number of Partnerships
8.1.7. Analysis by Local and International Agreements
8.1.8. Analysis by Intercontinental and Intracontinental Agreements
9. GRANTS ANALYSIS
9.1. Scope and Methodology
9.2. Key Parameters
9.3. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Grants Analysis
9.3.1. Analysis by Year of Grant Awarded
9.3.2. Analysis by Support Period
9.3.3. Analysis by Amount Awarded
9.3.4. Analysis by Leading Funding Institute Centre
9.3.5. Analysis by Type of Grant
9.3.6. Analysis by Activity Code
9.3.7. Analysis by Study Section Involved
9.3.8. Analysis by Purpose of Grant
9.3.9. Prominent Program Officers: Analysis by Number of Grants
9.3.10. Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
9.3.11. Most Popular Departments: Analysis by Number of Grants
9.3.12. Analysis by Location of Recipient
10. PUBLICATION ANALYSIS
10.1. Methodology and Parameters
10.2. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Publication Analysis
10.2.1. Analysis by Year of Publication
10.2.2. Analysis by Type of Publication
10.2.3. Most Popular Journals: Analysis by Number of Publications
10.2.4. Most Popular Journals: Analysis by Journal Impact Factor
10.2.5. Popular Keywords: Analysis by Key Focus Areas
10.2.6. Most Active Publishers: Analysis by Number of Publications
10.2.7. Most Popular Affiliations: Analysis by Number of Publications
10.2.8. Analysis by Geography
11. PORTER’S FIVE FORCES ANALYSIS
11.1. Chapter Overview
11.2. Methodology and Key Parameters
11.3. Porter’s Five Forces
11.3.1. Threat of New Entrants
11.3.2. Bargaining Power of End Users
11.3.3. Bargaining Power of Drug Developers
11.3.4. Threat of Substitute Products
11.3.5. Rivalry Among Existing Competitors
12. MARKET FORECAST: MONKEYPOX THERAPEUTICS AND VACCINES
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Monkeypox Therapeutics and Vaccines Market, 2023-2035
12.3.1. Monkeypox Therapeutics and Vaccines Market: Analysis by Type of Product, 2023 and 2035
12.3.1.1. Monkeypox Therapeutics Market, 2023-2035
12.3.1.2. Monkeypox Vaccines Market, 2023-2035
12.3.2. Monkeypox Therapeutics and Vaccines Market: Analysis by Drug Developers, 2023 and 2035
12.3.2.1. Monkeypox Therapeutics and Vaccines Market for Bavarian Nordic, 2023-2035
12.3.2.2. Monkeypox Therapeutics and Vaccines Market for Emergent BioSolutions, 2023-2035
12.3.2.3. Monkeypox Therapeutics and Vaccines Market for KM Biologics, 2023-2035
12.3.2.4. Monkeypox Therapeutics and Vaccines Market for SIGA Technologies, 2023-2035
12.3.3. Monkeypox Therapeutics and Vaccines Market: Analysis by Drug Candidates, 2023 and 2035
12.3.3.1. IMVANEX® / JYNNEOS® / IMVAMUNE® (Bavarian Nordic): Sales Forecast, 2023-2035
12.3.3.2. ACAM2000 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.3.3. LC16KMB (KM Biologics): Sales Forecast, 2023-2035
12.3.3.4. Tecovirimat / ST-246 / TPOXX (SIGA Technologies): Sales Forecast, 2023-2035
12.3.3.5. VIGIV / CNJ-016 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.4. Monkeypox Therapeutics and Vaccines Market: Analysis by Geography, 2023 and 2035
12.3.4.1. Monkeypox Therapeutics and Vaccines Market in North America, 2023-2035
12.3.4.1.1. Monkeypox Therapeutics and Vaccines Market in the US, 2023-2035
12.3.4.1.2. Monkeypox Therapeutics and Vaccines Market in Canada, 2023-2035
12.3.4.2. Monkeypox Therapeutics and Vaccines Market in Europe, 2023-2035
12.3.4.2.1. Monkeypox Therapeutics and Vaccines Market in the UK, 2023-2035
12.3.4.2.2. Monkeypox Therapeutics and Vaccines Market in Germany, 2023-2035
12.3.4.2.3. Monkeypox Therapeutics and Vaccines Market in Spain, 2023-2035
12.3.4.2.4. Monkeypox Therapeutics and Vaccines Market in France, 2023-2035
12.3.4.2.5. Monkeypox Therapeutics and Vaccines Market in Italy, 2023-2035
12.3.4.2.6. Monkeypox Therapeutics and Vaccines Market in Rest of Europe, 2023-2035
12.3.4.3. Monkeypox Therapeutics and Vaccines Market in Asia Pacific, 2023-2035
12.3.4.3.1. Monkeypox Therapeutics and Vaccines Market in Japan, 2023-2035
12.3.4.3.2. Monkeypox Therapeutics and Vaccines Market in Australia, 2023-2035
13. MARKET FORECAST: MONKEYPOX DIAGNOSTIC KITS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Monkeypox Diagnostic Kits Market, 2023-2028
13.3.1. Monkeypox Diagnostic Kits Market: Analysis by Type of Kit, 2023 and 2028
13.3.1.1. Monkeypox Polymerase Chain Reaction (PCR) Detection Kits Market, 2023-2028
13.3.1.2. Monkeypox Antigen Detection Kits Market, 2023-2028
13.3.1.3 Monkeypox Antibody Detection Kits Market, 2023-2028
13.3.2. Monkeypox Diagnostic Kits Market: Analysis by Type of End User, 2023 and 2028
13.3.2.1. Monkeypox Diagnostic Kits Market for Hospitals and Clinics, 2023-2028
13.3.2.2. Monkeypox Diagnostic Kits Market for Diagnostic Laboratories, 2023-2028
13.3.2.3. Monkeypox Diagnostic Kits Market for Other End Users, 2023-2028
13.3.3. Monkeypox Diagnostic Kits Market: Analysis by Geography, 2023 and 2028
13.3.3.1. Monkeypox Diagnostic Kits Market in North America, 2023-2028
13.3.3.1.1. Monkeypox Diagnostic Kits Market in the US, 2023-2028
13.3.3.1.2. Monkeypox Diagnostic Kits Market in Canada, 2023-2028
13.3.3.2. Monkeypox Diagnostic Kits Market in Europe, 2023-2028
13.3.3.2.1. Monkeypox Diagnostic Kits Market in the UK, 2023-2028
13.3.3.2.2. Monkeypox Diagnostic Kits in France, 2023-2028
13.3.3.2.3. Monkeypox Diagnostic Kits Market in Germany, 2023-2028
13.3.3.2.4. Monkeypox Diagnostic Kits Market in Spain, 2023-2028
13.3.3.2.5. Monkeypox Diagnostic Kits Market in Italy, 2023-2028
13.3.3.2.6. Monkeypox Diagnostic Kits Market in Rest of Europe, 2023-2028
13.3.3.3. Monkeypox Diagnostic Kits Market in Asia Pacific, 2023-2028
14. EXECUTIVE INSIGHTS
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
2. INTRODUCTION
2.1. An Overview of Monkeypox
2.2. Signs and Symptoms
2.3. History of Disease Outbreaks
2.4. Disease Transmission
2.5. Disease Diagnosis
2.6. Prevention and Treatment
2.6.1 Prevention Measures
2.6.2 Available Therapeutics and Vaccines
2.7. Future Perspectives
3. MARKET LANDSCAPE: MONKEYPOX THERAPEUTICS AND VACCINES
3.1. Monkeypox Therapeutics and Vaccines: Overall Market Landscape
3.1.1 Analysis by Phase of Development
3.1.2 Analysis by Type of Product
3.1.3 Analysis by Phase of Development and Type of Product
3.1.4 Analysis by Type of Molecule
3.1.5 Analysis by Type of Dosage Form
3.1.6 Analysis by Route of Administration
3.2. Monkeypox Therapeutics and Vaccines: Developer Landscape
3.2.1 Analysis by Year of Establishment
3.2.2 Analysis by Type of Player
3.2.3 Analysis by Geography (Region-wise)
3.2.4 Analysis by Company Size and Geography (Region-wise)
3.2.5 Leading Developers: Analysis by Number of Therapeutics / Vaccines
4. MARKET LANDSCAPE: MONKEYPOX DIAGNOSTIC KITS
4.1. Monkeypox Diagnostic Kits: Overall Market Landscape
4.1.1. Analysis by Type of Sample
4.1.2. Analysis by Type of Kit Component
4.1.3. Analysis by Clade of Virus Detected
4.1.4. Analysis by Detection Method
4.1.5. Analysis by Application Area
4.1.6. Analysis by Type of Kit
4.1.7. Analysis by Quantity of Sample
4.1.8. Analysis by Turnaround Time
4.1.9 Analysis by Limit of Detection
4.1.10. Analysis by Number of Tests per Kit
4.1.11 Analysis by Shelf Life
4.1.12 Analysis by Storage Temperature
4.2 Monkeypox Diagnostic Kits: Developer Landscape
4.2.1. Analysis by Year of Establishment
4.2.2. Analysis by Company Size
4.2.3. Analysis by Location of Headquarters
4.2.4. Analysis by Company Size and Location of Headquarters
4.2.5. Analysis by Type of Developer
4.2.6. Key Developers: Analysis by Number of Diagnostic Kits Developed
5. MONKEYPOX DIAGNOSTIC KITS: PRODUCT COMPETITIVENESS ANALYSIS
5.1. Methodology
5.2. Product Competitiveness Analysis: Monkeypox Diagnostic Kits
6. COMPANY PROFILES: MONKEYPOX THERAPEUTICS AND VACCINES DEVELOPERS
6.1. Bavarian Nordic
6.1.1. Company Overview
6.1.2. Monkeypox Therapeutics / Vaccines Portfolio
6.1.3. Recent Developments and Future Outlook
6.2. Emergent BioSolutions
6.2.1. Company Overview
6.2.2. Monkeypox Therapeutics / Vaccines Portfolio
6.2.3. Recent Developments and Future Outlook
7. COMPANY PROFILES: MONKEYPOX DIAGNOSTIC KITS DEVELOPERS
7.1. ACON Laboratories
7.1.1. Company Overview
7.1.2. Monkeypox Diagnostic Kits Portfolio
7.2. altona Diagnostics
7.2.1. Company Overview
7.2.2. Monkeypox Diagnostic Kits Portfolio
7.2.3. Recent Developments and Future Outlook
7.3. DNA Software
7.3.1. Company Overview
7.3.2. Monkeypox Diagnostic Kits Portfolio
7.4. Elabscience
7.4.1. Company Overview
7.4.2. Monkeypox Diagnostic Kits Portfolio
7.5. Goldsite Diagnostics
7.5.1. Company Overview
7.5.2. Monkeypox Diagnostic Kits Portfolio
7.6. Hangzhou Testsea Biotechnology
7.6.1. Company Overview
7.6.2. Monkeypox Diagnostic Kits Portfolio
7.6.3. Recent Developments and Future Outlook
7.7. Jiangsu Bioperfectus Technologies
7.7.1. Company Overview
7.7.2. Monkeypox Diagnostic Kits Portfolio
7.7.3. Recent Developments and Future Outlook
7.8. Lansion Biotechnology
7.8.1. Company Overview
7.8.2. Monkeypox Diagnostic Kits Portfolio
8. PARTNERSHIPS AND COLLABORATIONS
8.1. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Partnerships and Collaborations
8.1.1. Analysis by Year of Partnership
8.1.2. Analysis by Type of Partnership
8.1.3. Analysis by Year and Type of Partnership
8.1.4. Analysis by Focus Area
8.1.5. Analysis by Type of Partner
8.1.6. Most Active Players: Analysis by Number of Partnerships
8.1.7. Analysis by Local and International Agreements
8.1.8. Analysis by Intercontinental and Intracontinental Agreements
9. GRANTS ANALYSIS
9.1. Scope and Methodology
9.2. Key Parameters
9.3. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Grants Analysis
9.3.1. Analysis by Year of Grant Awarded
9.3.2. Analysis by Support Period
9.3.3. Analysis by Amount Awarded
9.3.4. Analysis by Leading Funding Institute Centre
9.3.5. Analysis by Type of Grant
9.3.6. Analysis by Activity Code
9.3.7. Analysis by Study Section Involved
9.3.8. Analysis by Purpose of Grant
9.3.9. Prominent Program Officers: Analysis by Number of Grants
9.3.10. Popular Recipient Organizations: Analysis by Number of Grants and Amount Awarded
9.3.11. Most Popular Departments: Analysis by Number of Grants
9.3.12. Analysis by Location of Recipient
10. PUBLICATION ANALYSIS
10.1. Methodology and Parameters
10.2. Monkeypox Therapeutics / Vaccines and Diagnostic Kits: Publication Analysis
10.2.1. Analysis by Year of Publication
10.2.2. Analysis by Type of Publication
10.2.3. Most Popular Journals: Analysis by Number of Publications
10.2.4. Most Popular Journals: Analysis by Journal Impact Factor
10.2.5. Popular Keywords: Analysis by Key Focus Areas
10.2.6. Most Active Publishers: Analysis by Number of Publications
10.2.7. Most Popular Affiliations: Analysis by Number of Publications
10.2.8. Analysis by Geography
11. PORTER’S FIVE FORCES ANALYSIS
11.1. Chapter Overview
11.2. Methodology and Key Parameters
11.3. Porter’s Five Forces
11.3.1. Threat of New Entrants
11.3.2. Bargaining Power of End Users
11.3.3. Bargaining Power of Drug Developers
11.3.4. Threat of Substitute Products
11.3.5. Rivalry Among Existing Competitors
12. MARKET FORECAST: MONKEYPOX THERAPEUTICS AND VACCINES
12.1. Chapter Overview
12.2. Key Assumptions and Forecast Methodology
12.3. Global Monkeypox Therapeutics and Vaccines Market, 2023-2035
12.3.1. Monkeypox Therapeutics and Vaccines Market: Analysis by Type of Product, 2023 and 2035
12.3.1.1. Monkeypox Therapeutics Market, 2023-2035
12.3.1.2. Monkeypox Vaccines Market, 2023-2035
12.3.2. Monkeypox Therapeutics and Vaccines Market: Analysis by Drug Developers, 2023 and 2035
12.3.2.1. Monkeypox Therapeutics and Vaccines Market for Bavarian Nordic, 2023-2035
12.3.2.2. Monkeypox Therapeutics and Vaccines Market for Emergent BioSolutions, 2023-2035
12.3.2.3. Monkeypox Therapeutics and Vaccines Market for KM Biologics, 2023-2035
12.3.2.4. Monkeypox Therapeutics and Vaccines Market for SIGA Technologies, 2023-2035
12.3.3. Monkeypox Therapeutics and Vaccines Market: Analysis by Drug Candidates, 2023 and 2035
12.3.3.1. IMVANEX® / JYNNEOS® / IMVAMUNE® (Bavarian Nordic): Sales Forecast, 2023-2035
12.3.3.2. ACAM2000 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.3.3. LC16KMB (KM Biologics): Sales Forecast, 2023-2035
12.3.3.4. Tecovirimat / ST-246 / TPOXX (SIGA Technologies): Sales Forecast, 2023-2035
12.3.3.5. VIGIV / CNJ-016 (Emergent BioSolutions): Sales Forecast, 2023-2035
12.3.4. Monkeypox Therapeutics and Vaccines Market: Analysis by Geography, 2023 and 2035
12.3.4.1. Monkeypox Therapeutics and Vaccines Market in North America, 2023-2035
12.3.4.1.1. Monkeypox Therapeutics and Vaccines Market in the US, 2023-2035
12.3.4.1.2. Monkeypox Therapeutics and Vaccines Market in Canada, 2023-2035
12.3.4.2. Monkeypox Therapeutics and Vaccines Market in Europe, 2023-2035
12.3.4.2.1. Monkeypox Therapeutics and Vaccines Market in the UK, 2023-2035
12.3.4.2.2. Monkeypox Therapeutics and Vaccines Market in Germany, 2023-2035
12.3.4.2.3. Monkeypox Therapeutics and Vaccines Market in Spain, 2023-2035
12.3.4.2.4. Monkeypox Therapeutics and Vaccines Market in France, 2023-2035
12.3.4.2.5. Monkeypox Therapeutics and Vaccines Market in Italy, 2023-2035
12.3.4.2.6. Monkeypox Therapeutics and Vaccines Market in Rest of Europe, 2023-2035
12.3.4.3. Monkeypox Therapeutics and Vaccines Market in Asia Pacific, 2023-2035
12.3.4.3.1. Monkeypox Therapeutics and Vaccines Market in Japan, 2023-2035
12.3.4.3.2. Monkeypox Therapeutics and Vaccines Market in Australia, 2023-2035
13. MARKET FORECAST: MONKEYPOX DIAGNOSTIC KITS
13.1. Chapter Overview
13.2. Key Assumptions and Forecast Methodology
13.3. Global Monkeypox Diagnostic Kits Market, 2023-2028
13.3.1. Monkeypox Diagnostic Kits Market: Analysis by Type of Kit, 2023 and 2028
13.3.1.1. Monkeypox Polymerase Chain Reaction (PCR) Detection Kits Market, 2023-2028
13.3.1.2. Monkeypox Antigen Detection Kits Market, 2023-2028
13.3.1.3 Monkeypox Antibody Detection Kits Market, 2023-2028
13.3.2. Monkeypox Diagnostic Kits Market: Analysis by Type of End User, 2023 and 2028
13.3.2.1. Monkeypox Diagnostic Kits Market for Hospitals and Clinics, 2023-2028
13.3.2.2. Monkeypox Diagnostic Kits Market for Diagnostic Laboratories, 2023-2028
13.3.2.3. Monkeypox Diagnostic Kits Market for Other End Users, 2023-2028
13.3.3. Monkeypox Diagnostic Kits Market: Analysis by Geography, 2023 and 2028
13.3.3.1. Monkeypox Diagnostic Kits Market in North America, 2023-2028
13.3.3.1.1. Monkeypox Diagnostic Kits Market in the US, 2023-2028
13.3.3.1.2. Monkeypox Diagnostic Kits Market in Canada, 2023-2028
13.3.3.2. Monkeypox Diagnostic Kits Market in Europe, 2023-2028
13.3.3.2.1. Monkeypox Diagnostic Kits Market in the UK, 2023-2028
13.3.3.2.2. Monkeypox Diagnostic Kits in France, 2023-2028
13.3.3.2.3. Monkeypox Diagnostic Kits Market in Germany, 2023-2028
13.3.3.2.4. Monkeypox Diagnostic Kits Market in Spain, 2023-2028
13.3.3.2.5. Monkeypox Diagnostic Kits Market in Italy, 2023-2028
13.3.3.2.6. Monkeypox Diagnostic Kits Market in Rest of Europe, 2023-2028
13.3.3.3. Monkeypox Diagnostic Kits Market in Asia Pacific, 2023-2028
14. EXECUTIVE INSIGHTS
15. APPENDIX 1: TABULATED DATA
16. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
